The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The FDA-approved drug sofosbuvir inhibits Zika virus infection
Open accessAbstract
&NA; The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with severe cases causing Guillain‐Barré syndrome, congenital malformations, and microcephaly. Currently, there is no available vaccine or therapy to prevent or treat ZIKV infection. We evaluated whether sofosbuvir, an FDA‐approved nucleotide polymerase inhibitor for the distantly related hepatitis C virus, could have antiviral activity against ZIKV infection. Cell culture studies established that sofosbuvir efficiently inhibits replication and infection of several ZIKV strains in multiple human tumor cell lines and isolated human fetal‐derived neuronal stem cells. Moreover, oral treatment with sofosbuvir protected against ZIKV‐induced death in mice. These results suggest that sofosbuvir may be a candidate for further evaluation as a therapy against ZIKV infection in humans. HighlightsSofosbuvir reduces replication of multiple ZIKV isolates in human liver and placental cells.Sofosbuvir protects human neuronal stem cells from ZIKV infection.Oral administration of sofosbuvir via drinking reduces ZIKV death in mice.Sofosbuvir should be evaluated as an anti‐ZIKV treatment in non‐rodent species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characterization of Lethal Zika Virus Infection in AG129 Mice
Aliota, M. T., Caine, E. A., Walker, E. C., Larkin, K. E., Camacho, E., & Osorio, J. E. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004682 · Cited by 322
Guillain-Barre syndrome associated with Zika virus infection
Brasil, P., Sequeira, P. C., Freitas, A. D., Zogbi, H. E., Calvet, G. A., de Souza, R. V., Siqueira, A. M., de Mendonca, M. C. L., Nogueira, R. M. R., de Filippis, A. M. B., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30058-7 · Cited by 299
Onorati, M., Li, Z., Liu, F., Sousa, A. M. M., Nakagawa, N., Li, M., Dell’Anno, M. T., Gulden, F. O., Pochareddy, S., Tebbenkamp, A. T. N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.038 · Cited by 292
Cited by
The continued threat of emerging flaviviruses
Pierson, T. C., & Diamond, M. S. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0714-0 · Cited by 1,098
Self-citationAnti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715
Animal Models of Zika Virus Infection, Pathogenesis, and Immunity
Morrison, T. E., & Diamond, M. S. (2017) · Journal of Virology · doi:10.1128/jvi.00009-17 · Cited by 275
Self-citationDrug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli, B., Palù, G., & Loregian, A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.04.004 · Cited by 264
Overview on the Current Status of Zika Virus Pathogenesis and Animal Related Research
Pawitwar, S. S., Dhar, S., Tiwari, S., Ojha, C. R., Lapierre, J., Martins, K., Rodzinski, A., Parira, T., Paudel, I., Li, J., et al. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9743-8 · Cited by 30
Metadata
- Authors
- Bullard-Feibelman, K. M., Govero, J., Zhu, Z., Salazar, V., Veselinovic, M., Diamond, M. S., & Geiss, B. J.
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 137
- Pages
- 134-140
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W2552845139
- Cited by
- 246
- References
- 3
- FWCI
- 36.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FDA-approved drug sofosbuvir inhibits Zika virus infection. https://app.cochat.ai/papers/10.1016/j.antiviral.2016.11.023
- The paper
- Bullard-Feibelman, K. M., Govero, J., Zhu, Z., Salazar, V., Veselinovic, M., Diamond, M. S., & Geiss, B. J. (2017). The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Research. https://doi.org/10.1016/j.antiviral.2016.11.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.